Kings Point Capital Management’s Novo Nordisk NVO Stock Holding History

Kings Point Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,384	Closed	-$37K	–	329
2016 Q2	$37K	Hold	1,384	–	–	0.01%	212
2016 Q1	$37K	Hold	1,384	–	–	0.01%	204
2015 Q4	$40K	Hold	1,384	–	–	0.01%	228
2015 Q3	$38K	Hold	1,384	–	–	0.01%	249
2015 Q2	$38K	Hold	1,384	–	–	0.01%	241
2015 Q1	$37K	Hold	1,384	–	–	0.01%	249
2014 Q4	$29K	Buy	+1,384	New	+$30.9K	0.01%	251

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Kings Point Capital Management's NVO Position: Q3 2016 in Review

Kings Point Capital Management sold out of Novo Nordisk (NVO) in Q3 2016, closing a stake of 1,384 shares — an estimated $37K sold.

Kings Point Capital Management first reported a position in NVO in Q4 2014 and held it in 7 quarters. The position peaked at $40K in Q4 2015. 513 funds tracked by Wall St. Rank hold NVO as of Q3 2016.

Kings Point Capital Management reported no remaining Novo Nordisk position as of Q3 2016 after selling out during the quarter.
Kings Point Capital Management sold 1,384 Novo Nordisk shares in Q3 2016, an estimated $37K.
Kings Point Capital Management first reported a position in Novo Nordisk in Q4 2014 and held it in 7 quarters.
Kings Point Capital Management's Novo Nordisk position peaked at $40K in Q4 2015.
513 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2016.

Based on Kings Point Capital Management's 13F filing for Q3 2016, filed 4 Nov 2016.